Vertex Pharmaceuticals Key Executives
This section highlights Vertex Pharmaceuticals's key executives, including their titles and compensation details.
Find Contacts at Vertex Pharmaceuticals
( total contacts)
Vertex Pharmaceuticals Earnings
This section highlights Vertex Pharmaceuticals's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-10 | $4.02 | $3.98 |
| Read Transcript | Q3 | 2024 | 2024-11-04 | $4.14 | $4.38 |
| Read Transcript | Q2 | 2024 | 2024-08-01 | $-11.63 | $-12.83 |
| Read Transcript | Q1 | 2024 | 2024-05-06 | $4.06 | $4.76 |
| Read Transcript | Q4 | 2023 | 2024-02-05 | $4.10 | $4.20 |
| Read Transcript | Q3 | 2023 | 2023-11-06 | $3.97 | $4.08 |
| Read Transcript | Q2 | 2023 | 2023-08-01 | $3.88 | $3.89 |
| Read Transcript | Q1 | 2023 | 2023-05-01 | $3.00 | $3.05 |
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
$512.52
Stock Price
$131.61B
Market Cap
94.00K
Employees
Boston, MA
Location
Financial Statements
Access annual & quarterly financial statements for Vertex Pharmaceuticals, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $11.02B | $9.87B | $8.93B | $7.57B | $6.21B |
| Cost of Revenue | $1.53B | $1.26B | $1.08B | $904.20M | $736.30M |
| Gross Profit | $9.49B | $8.61B | $7.85B | $6.67B | $5.47B |
| Gross Profit Ratio | 86.11% | 87.20% | 87.90% | 88.10% | 88.14% |
| Research and Development Expenses | $3.63B | $3.16B | $2.54B | $3.05B | $1.83B |
| General and Administrative Expenses | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $1.46B | $1.14B | $944.70M | $840.10M | $770.46M |
| Other Expenses | $4.63B | $475.50M | $-164.80M | $4.90M | $296.42M |
| Operating Expenses | $9.72B | $4.78B | $3.48B | $3.89B | $2.60B |
| Cost and Expenses | $11.25B | $6.04B | $4.57B | $4.80B | $3.34B |
| Interest Income | $598.10M | $614.70M | $144.60M | $4.90M | $22.24M |
| Interest Expense | $30.60M | $44.10M | $54.80M | $61.50M | $58.15M |
| Depreciation and Amortization | $207.20M | $181.30M | $148.30M | $125.60M | $109.52M |
| EBITDA | $486.30M | $4.61B | $4.44B | $2.92B | $3.28B |
| EBITDA Ratio | 4.41% | 46.66% | 48.65% | 36.82% | 51.37% |
| Operating Income | $-232.90M | $4.31B | $4.31B | $2.78B | $2.86B |
| Operating Income Ratio | -2.11% | 43.65% | 48.23% | 36.73% | 46.03% |
| Total Other Income Expenses Net | $481.40M | $72.30M | $-75.00M | $-51.70M | $62.80M |
| Income Before Tax | $248.50M | $4.38B | $4.23B | $2.73B | $3.12B |
| Income Before Tax Ratio | 2.25% | 44.38% | 47.39% | 36.05% | 50.22% |
| Income Tax Expense | $784.10M | $760.20M | $910.40M | $388.30M | $405.15M |
| Net Income | $-535.60M | $3.62B | $3.32B | $2.34B | $2.71B |
| Net Income Ratio | -4.86% | 36.68% | 37.20% | 30.92% | 43.70% |
| EPS | $-2.08 | $14.05 | $12.97 | $9.09 | $10.44 |
| EPS Diluted | $-2.08 | $13.89 | $12.82 | $9.01 | $10.29 |
| Weighted Average Shares Outstanding | 257.50M | 257.70M | 256.10M | 257.70M | 259.84M |
| Weighted Average Shares Outstanding Diluted | 257.90M | 260.50M | 259.10M | 259.90M | 263.40M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.91B | $2.77B | $2.63B | $2.69B | $2.52B | $2.48B | $2.49B | $2.37B | $2.30B | $2.33B | $2.20B | $2.10B | $2.07B | $1.98B | $1.79B | $1.72B | $1.63B | $1.54B | $1.52B | $1.52B |
| Cost of Revenue | $423.40M | $392.60M | $371.90M | $342.60M | $368.00M | $318.70M | $308.60M | $266.90M | $283.30M | $289.40M | $261.80M | $245.80M | $247.40M | $236.51M | $227.97M | $192.33M | $203.10M | $186.18M | $184.52M | $162.50M |
| Gross Profit | $2.49B | $2.38B | $2.26B | $2.34B | $2.15B | $2.16B | $2.18B | $2.11B | $2.02B | $2.04B | $1.93B | $1.85B | $1.83B | $1.75B | $1.57B | $1.53B | $1.42B | $1.35B | $1.34B | $1.35B |
| Gross Profit Ratio | 85.46% | 85.80% | 85.90% | 87.30% | 85.40% | 87.20% | 87.60% | 88.80% | 87.70% | 87.60% | 88.10% | 88.30% | 88.10% | 88.10% | 87.30% | 88.80% | 87.52% | 87.90% | 87.90% | 89.27% |
| Research and Development Expenses | $998.70M | $875.90M | $5.42B | $865.90M | $821.80M | $810.00M | $785.70M | $742.60M | $694.10M | $645.00M | $600.10M | $603.10M | $694.30M | $493.75M | $1.41B | $455.97M | $466.58M | $493.50M | $420.93M | $448.53M |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $377.60M | $371.80M | $372.20M | $342.70M | $369.10M | $263.80M | $262.60M | $241.10M | $267.40M | $246.80M | $215.30M | $215.20M | $255.20M | $198.19M | $194.67M | $192.08M | $211.84M | $184.55M | $191.80M | $182.26M |
| Other Expenses | $86.30M | $15.30M | $-23.10M | $-31.20M | $-9.80M | $-15.90M | $1.60M | $1.30M | $24.40M | $17.20M | $-78.10M | $-72.80M | $7.10M | $42.37M | $8.05M | $-52.65M | $156.80M | $84.39M | $116.36M | $-61.13M |
| Operating Expenses | $1.46B | $1.26B | $5.79B | $1.21B | $1.19B | $1.07B | $1.05B | $983.70M | $985.90M | $891.80M | $815.40M | $818.30M | $949.50M | $691.94M | $1.60B | $648.05M | $678.43M | $678.05M | $612.73M | $630.79M |
| Cost and Expenses | $1.89B | $1.66B | $6.16B | $1.55B | $1.56B | $1.39B | $1.36B | $1.25B | $1.27B | $1.18B | $1.08B | $1.06B | $1.20B | $928.45M | $1.83B | $840.38M | $881.53M | $864.23M | $797.25M | $793.28M |
| Interest Income | $128.20M | $132.20M | $156.50M | $181.20M | $179.50M | $167.90M | $144.70M | $122.60M | $86.00M | $46.20M | $10.80M | $1.60M | $1.20M | $1.12M | $1.13M | $1.47M | $2.32M | $3.10M | $4.24M | $12.58M |
| Interest Expense | $2.80M | $7.50M | $9.90M | $10.40M | $10.60M | $10.90M | $11.20M | $11.40M | $11.60M | $13.70M | $14.60M | $14.90M | $15.10M | $15.26M | $15.48M | $15.68M | $16.29M | $13.86M | $13.87M | $14.14M |
| Depreciation and Amortization | $46.50M | $53.20M | $54.00M | $53.50M | $59.00M | $42.10M | $41.40M | $38.80M | $38.40M | $36.70M | $-54.60M | $-78.70M | $33.83M | $31.70M | $31.24M | $28.83M | $29.36M | $26.64M | $26.70M | $26.82M |
| EBITDA | $1.19B | $1.28B | $-3.33B | $1.34B | $1.22B | $1.23B | $1.21B | $941.70M | $1.10B | $1.23B | $1.08B | $1.01B | $919.83M | $1.13B | $2.46M | $865.47M | $934.27M | $786.37M | $865.34M | $698.49M |
| EBITDA Ratio | 40.72% | 46.35% | -131.75% | 44.27% | 40.43% | 50.05% | 51.44% | 52.56% | 47.61% | 52.11% | 47.89% | 45.87% | 42.65% | 55.40% | -1.52% | 48.29% | 55.62% | 49.51% | 55.61% | 44.44% |
| Operating Income | $1.03B | $1.12B | $-3.53B | $1.14B | $958.80M | $1.04B | $1.03B | $779.00M | $1.03B | $1.13B | $1.11B | $1.04B | $877.70M | $1.05B | $-37.96M | $887.83M | $745.79M | $672.24M | $718.03M | $720.22M |
| Operating Income Ratio | 35.23% | 40.27% | -133.80% | 42.27% | 38.08% | 41.80% | 41.17% | 32.80% | 44.88% | 48.27% | 50.37% | 49.63% | 42.35% | 53.15% | -2.12% | 51.49% | 45.82% | 43.70% | 47.10% | 47.54% |
| Total Other Income Expenses Net | $110.50M | $107.80M | $123.50M | $139.60M | $159.10M | $141.10M | $135.10M | $112.50M | $43.30M | $49.70M | $-81.90M | $-86.10M | $-6.82M | $341.00K | $-6.29M | $-66.84M | $142.83M | $73.63M | $106.74M | $-62.69M |
| Income Before Tax | $1.14B | $1.22B | $-3.39B | $1.28B | $1.15B | $1.18B | $1.16B | $891.50M | $1.08B | $1.18B | $1.02B | $954.80M | $870.90M | $1.08B | $-44.26M | $820.96M | $888.62M | $745.87M | $824.77M | $657.53M |
| Income Before Tax Ratio | 39.03% | 44.16% | -128.71% | 47.60% | 45.58% | 47.48% | 46.59% | 37.54% | 46.76% | 50.40% | 46.64% | 45.52% | 42.02% | 54.57% | -2.47% | 47.61% | 54.59% | 48.49% | 54.10% | 43.40% |
| Income Tax Expense | $223.50M | $178.70M | $202.40M | $179.50M | $178.80M | $143.90M | $245.80M | $191.70M | $257.90M | $245.90M | $213.90M | $192.70M | $100.80M | $230.81M | $-111.18M | $167.82M | $284.43M | $78.44M | $-12.50M | $54.78M |
| Net Income | $913.00M | $1.05B | $-3.59B | $1.10B | $968.80M | $1.04B | $915.70M | $699.80M | $818.90M | $930.50M | $810.50M | $762.10M | $770.10M | $851.93M | $66.92M | $653.14M | $604.19M | $667.43M | $837.27M | $602.75M |
| Net Income Ratio | 31.35% | 37.71% | -136.40% | 40.92% | 38.48% | 41.69% | 36.73% | 29.47% | 35.56% | 39.86% | 36.90% | 36.33% | 37.16% | 42.94% | 3.73% | 37.88% | 37.12% | 43.39% | 54.92% | 39.78% |
| EPS | $3.55 | $4.05 | $-13.92 | $4.26 | $3.76 | $4.01 | $3.55 | $2.72 | $3.19 | $3.63 | $3.17 | $2.99 | $3.02 | $3.30 | $0.26 | $2.52 | $2.32 | $2.56 | $3.22 | $2.32 |
| EPS Diluted | $3.50 | $4.01 | $-13.92 | $4.21 | $3.71 | $3.97 | $3.52 | $2.69 | $3.15 | $3.59 | $3.13 | $2.96 | $3.00 | $3.28 | $0.26 | $2.49 | $2.30 | $2.53 | $3.18 | $2.29 |
| Weighted Average Shares Outstanding | 257.50M | 258.00M | 258.10M | 258.20M | 257.70M | 258.00M | 257.70M | 257.40M | 256.90M | 256.50M | 255.90M | 255.10M | 254.60M | 257.88M | 258.99M | 259.37M | 260.04M | 260.39M | 259.64M | 259.81M |
| Weighted Average Shares Outstanding Diluted | 260.50M | 261.00M | 258.10M | 261.10M | 260.90M | 260.60M | 260.40M | 260.30M | 260.30M | 259.50M | 258.70M | 257.90M | 257.00M | 259.71M | 261.02M | 261.92M | 263.11M | 264.08M | 263.40M | 263.51M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $4.57B | $10.37B | $10.50B | $6.79B | $5.99B |
| Short Term Investments | $1.55B | $849.20M | $274.50M | $729.90M | $670.71M |
| Cash and Short Term Investments | $6.12B | $11.22B | $10.78B | $7.52B | $6.66B |
| Net Receivables | $1.61B | $1.56B | $1.44B | $1.14B | $885.35M |
| Inventory | $1.21B | $738.80M | $460.60M | $353.10M | $280.78M |
| Other Current Assets | $665.70M | $623.70M | $553.50M | $545.80M | $308.30M |
| Total Current Assets | $9.60B | $14.14B | $12.68B | $9.01B | $7.83B |
| Property Plant Equipment Net | $2.58B | $1.45B | $1.11B | $1.09B | $958.53M |
| Goodwill | $1.09B | $1.09B | $1.09B | $1.40B | $1.40B |
| Intangible Assets | $825.90M | $839.90M | $603.60M | $400.00M | $400.00M |
| Goodwill and Intangible Assets | $1.91B | $1.93B | $1.69B | $1.40B | $1.40B |
| Long Term Investments | $5.11B | $2.60B | $99.40M | $85.80M | $20.80M |
| Tax Assets | $2.33B | $1.81B | $1.25B | $934.50M | $882.78M |
| Other Non-Current Assets | $999.30M | $796.70M | $1.32B | $901.10M | $662.51M |
| Total Non-Current Assets | $12.94B | $8.59B | $5.47B | $4.42B | $3.93B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $22.53B | $22.73B | $18.15B | $13.43B | $11.75B |
| Account Payables | $413.00M | $364.90M | $303.90M | $195.00M | $155.14M |
| Short Term Debt | $92.30M | $83.70M | $89.40M | $80.20M | $-274.99M |
| Tax Payables | $161.10M | $99.50M | $123.30M | $211.30M | $104.17M |
| Deferred Revenue | $- | $170.30M | $159.60M | $171.70M | $191.52M |
| Other Current Liabilities | $2.90B | $2.83B | $2.23B | $1.66B | $1.07B |
| Total Current Liabilities | $3.56B | $3.55B | $2.43B | $1.87B | $1.56B |
| Long Term Debt | $1.66B | $724.70M | $810.30M | $887.20M | $889.50M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $901.80M | $877.70M | $685.80M | $303.30M | $297.96M |
| Total Non-Current Liabilities | $2.56B | $1.60B | $1.81B | $1.46B | $1.50B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $6.12B | $5.15B | $4.24B | $3.33B | $3.06B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $2.60M | $2.60M | $2.60M | $2.50M | $2.60M |
| Retained Earnings | $9.61B | $10.14B | $6.52B | $3.20B | $858.67M |
| Accumulated Other Comprehensive Income Loss | $127.80M | $-14.30M | $800.00K | $15.90M | $-68.48M |
| Other Total Stockholders Equity | $6.67B | $7.45B | $7.39B | $6.88B | $7.89B |
| Total Stockholders Equity | $16.41B | $17.58B | $13.91B | $10.10B | $8.69B |
| Total Equity | $16.41B | $17.58B | $13.91B | $10.10B | $8.69B |
| Total Liabilities and Stockholders Equity | $22.53B | $22.73B | $18.15B | $13.43B | $11.75B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $22.53B | $22.73B | $18.15B | $13.43B | $11.75B |
| Total Investments | $6.65B | $3.45B | $274.50M | $729.90M | $670.71M |
| Total Debt | $1.75B | $808.40M | $561.00M | $556.70M | $581.48M |
| Net Debt | $-2.82B | $-9.56B | $-9.94B | $-6.24B | $-5.41B |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $4.57B | $5.24B | $4.58B | $9.16B | $10.37B | $11.11B | $10.15B | $9.29B | $10.50B | $9.17B | $8.70B | $7.60B | $6.79B | $6.28B | $6.06B | $6.30B | $5.99B | $5.36B | $4.83B | $3.59B |
| Short Term Investments | $1.55B | $1.29B | $1.22B | $1.01B | $849.20M | $11.93B | $11.24B | $1.12B | $274.50M | $599.20M | $551.20M | $638.00M | $729.90M | $685.19M | $644.32M | $619.64M | $670.71M | $792.97M | $619.44M | $596.98M |
| Cash and Short Term Investments | $6.12B | $6.52B | $5.80B | $10.17B | $11.22B | $11.93B | $11.24B | $10.41B | $10.78B | $9.77B | $9.25B | $8.24B | $7.52B | $6.96B | $6.71B | $6.92B | $6.66B | $6.15B | $5.45B | $4.19B |
| Net Receivables | $1.61B | $1.75B | $1.66B | $1.79B | $1.56B | $1.54B | $1.56B | $1.55B | $1.44B | $1.39B | $1.33B | $1.29B | $1.14B | $1.10B | $929.14M | $977.55M | $885.35M | $791.92M | $791.77M | $845.27M |
| Inventory | $1.21B | $1.08B | $914.60M | $813.10M | $738.80M | $688.70M | $603.50M | $535.10M | $460.60M | $388.20M | $367.70M | $338.90M | $353.10M | $333.46M | $321.62M | $298.86M | $280.78M | $245.46M | $219.22M | $187.09M |
| Other Current Assets | $665.70M | $449.20M | $575.40M | $511.10M | $623.70M | $540.20M | $476.90M | $468.70M | $553.50M | $1.45B | $549.50M | $491.50M | $545.80M | $915.65M | $498.76M | $677.85M | $308.30M | $270.02M | $232.56M | $223.65M |
| Total Current Assets | $9.60B | $9.80B | $8.94B | $13.29B | $14.14B | $14.70B | $13.87B | $12.97B | $13.23B | $11.54B | $10.95B | $9.87B | $9.01B | $8.39B | $7.96B | $8.20B | $7.83B | $7.19B | $6.46B | $5.22B |
| Property Plant Equipment Net | $2.58B | $2.51B | $1.77B | $1.49B | $1.45B | $1.43B | $1.45B | $1.45B | $1.46B | $1.12B | $1.10B | $1.11B | $1.09B | $1.04B | $1.02B | $986.12M | $958.53M | $920.91M | $728.36M | $736.30M |
| Goodwill | $1.09B | $1.09B | $1.09B | $1.09B | $1.09B | $1.09B | $1.09B | $1.09B | $1.09B | $1.08B | $1.39B | $1.40B | $1.40B | $1.40B | $1.40B | $1.40B | $1.40B | $1.40B | $1.40B | $1.40B |
| Intangible Assets | $825.90M | $831.60M | $837.50M | $834.90M | $839.90M | $603.60M | $603.60M | $603.60M | $603.60M | $603.60M | $387.00M | $400.00M | $400.00M | $400.00M | $400.00M | $400.00M | $400.00M | $400.00M | $400.00M | $400.00M |
| Goodwill and Intangible Assets | $1.91B | $1.92B | $1.93B | $1.92B | $1.93B | $1.69B | $1.69B | $1.69B | $1.69B | $1.68B | $1.39B | $1.40B | $1.40B | $1.40B | $1.40B | $1.40B | $1.40B | $1.40B | $1.40B | $1.40B |
| Long Term Investments | $5.11B | $4.70B | $4.40B | $4.46B | $2.60B | $1.70B | $1.36B | $1.08B | $112.20M | $107.70M | $102.70M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $2.33B | $2.31B | $2.19B | $1.96B | $1.81B | $1.73B | $1.54B | $1.36B | $1.25B | $1.16B | $1.14B | $945.50M | $934.50M | $933.84M | $952.81M | $815.89M | $882.78M | $1.15B | $1.21B | $1.15B |
| Other Non-Current Assets | $999.30M | $990.20M | $910.80M | $801.40M | $796.70M | $475.20M | $442.70M | $427.50M | $409.60M | $1.09B | $892.40M | $931.20M | $986.90M | $845.69M | $886.73M | $710.51M | $683.31M | $642.31M | $409.13M | $384.28M |
| Total Non-Current Assets | $12.94B | $12.44B | $11.19B | $10.63B | $8.59B | $7.03B | $6.48B | $6.01B | $4.92B | $5.16B | $4.63B | $4.39B | $4.42B | $4.22B | $4.26B | $3.91B | $3.93B | $4.11B | $3.75B | $3.67B |
| Other Assets | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $22.53B | $22.24B | $20.13B | $23.92B | $22.73B | $21.73B | $20.35B | $18.97B | $18.15B | $16.71B | $15.58B | $14.26B | $13.43B | $12.62B | $12.22B | $12.12B | $11.75B | $11.30B | $10.22B | $8.89B |
| Account Payables | $413.00M | $395.80M | $327.90M | $351.40M | $364.90M | $375.90M | $363.00M | $323.20M | $303.90M | $126.90M | $198.00M | $173.60M | $195.00M | $127.86M | $127.53M | $127.84M | $155.14M | $107.79M | $101.45M | $100.70M |
| Short Term Debt | $92.30M | $- | $- | $- | $83.70M | $- | $- | $- | $89.40M | $- | $- | $- | $80.20M | $- | $- | $- | $-274.99M | $- | $- | $- |
| Tax Payables | $161.10M | $- | $- | $- | $99.50M | $- | $- | $- | $123.30M | $- | $- | $- | $211.30M | $- | $- | $- | $104.17M | $- | $- | $- |
| Deferred Revenue | $206.80M | $- | $128.30M | $275.80M | $170.30M | $- | $- | $- | $159.60M | $- | $- | $- | $171.70M | $- | $- | $- | $191.52M | $- | $- | $- |
| Other Current Liabilities | $2.69B | $3.58B | $3.22B | $3.44B | $2.83B | $3.22B | $2.99B | $2.70B | $2.07B | $2.48B | $2.36B | $2.01B | $1.66B | $1.79B | $1.71B | $1.82B | $1.07B | $1.90B | $1.70B | $1.44B |
| Total Current Liabilities | $3.56B | $3.97B | $3.55B | $3.80B | $3.55B | $3.60B | $3.35B | $3.03B | $2.74B | $2.39B | $2.32B | $1.89B | $1.87B | $1.71B | $1.61B | $1.66B | $1.56B | $1.81B | $1.65B | $1.36B |
| Long Term Debt | $1.66B | $1.70B | $1.87B | $1.44B | $1.45B | $1.49B | $1.54B | $1.58B | $810.30M | $824.60M | $847.30M | $872.50M | $887.20M | $876.80M | $893.85M | $898.80M | $889.50M | $546.51M | $522.07M | $532.95M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $-924.10M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $924.10M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $901.80M | $933.30M | $-56.60M | $132.30M | $153.00M | $124.60M | $-8.30M | $-62.70M | $685.80M | $242.90M | $245.20M | $296.40M | $303.30M | $296.97M | $294.99M | $291.96M | $297.96M | $617.62M | $376.42M | $359.85M |
| Total Non-Current Liabilities | $2.56B | $2.64B | $1.81B | $1.57B | $1.60B | $1.61B | $1.53B | $1.52B | $1.50B | $1.29B | $1.33B | $1.46B | $1.46B | $1.38B | $1.42B | $1.47B | $1.50B | $1.36B | $1.05B | $1.07B |
| Other Liabilities | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $6.12B | $6.61B | $5.36B | $5.37B | $5.15B | $5.21B | $4.88B | $4.54B | $4.24B | $3.68B | $3.65B | $3.35B | $3.33B | $3.09B | $3.03B | $3.13B | $3.06B | $3.17B | $2.70B | $2.43B |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $2.60M | $2.60M | $2.60M | $2.60M | $2.60M | $257.80M | $257.80M | $2.60M | $2.60M | $2.60M | $2.60M | $2.60M | $2.50M | $2.56M | $2.59M | $2.59M | $2.60M | $2.60M | $2.60M | $2.59M |
| Retained Earnings | $9.61B | $8.69B | $7.65B | $11.24B | $10.14B | $9.17B | $8.14B | $7.22B | $6.52B | $5.70B | $4.77B | $3.96B | $3.20B | $2.43B | $1.58B | $1.51B | $858.67M | $254.48M | $-412.95M | $-1.25B |
| Accumulated Other Comprehensive Income Loss | $127.80M | $28.80M | $22.50M | $17.30M | $-14.30M | $-3.00M | $-39.80M | $-13.10M | $800.00K | $97.60M | $57.50M | $11.30M | $15.90M | $11.54M | $-25.16M | $-33.30M | $-68.48M | $-40.98M | $-14.12M | $13.38M |
| Other Total Stockholders Equity | $6.67B | $6.91B | $7.10B | $7.28B | $7.45B | $7.34B | $7.37B | $7.22B | $7.39B | $7.23B | $7.10B | $6.93B | $6.88B | $7.09B | $7.64B | $7.50B | $7.89B | $7.92B | $7.94B | $7.70B |
| Total Stockholders Equity | $16.41B | $15.63B | $14.77B | $18.55B | $17.58B | $16.51B | $15.47B | $14.43B | $13.91B | $13.03B | $11.93B | $10.91B | $10.10B | $9.53B | $9.20B | $8.98B | $8.69B | $8.13B | $7.52B | $6.46B |
| Total Equity | $16.41B | $15.63B | $14.77B | $18.55B | $17.58B | $16.51B | $15.47B | $14.43B | $13.91B | $13.03B | $11.93B | $10.91B | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Stockholders Equity | $22.53B | $22.24B | $20.13B | $23.92B | $22.73B | $21.73B | $20.35B | $18.97B | $18.15B | $16.71B | $15.58B | $14.26B | $13.43B | $12.62B | $12.22B | $12.12B | $11.75B | $11.30B | $10.22B | $8.89B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $22.53B | $22.24B | $20.13B | $23.92B | $22.73B | $21.73B | $20.35B | $18.97B | $18.15B | $16.71B | $15.58B | $14.26B | $13.43B | $12.62B | $12.22B | $12.12B | $11.75B | $11.30B | $10.22B | $8.89B |
| Total Investments | $6.65B | $5.99B | $5.61B | $5.47B | $3.45B | $13.63B | $12.59B | $2.21B | $386.70M | $599.20M | $551.20M | $638.00M | $729.90M | $685.19M | $644.32M | $619.64M | $670.71M | $792.97M | $619.44M | $596.98M |
| Total Debt | $1.75B | $1.70B | $933.40M | $721.30M | $808.40M | $744.70M | $767.60M | $789.20M | $899.70M | $482.00M | $531.60M | $544.20M | $556.70M | $558.93M | $569.75M | $572.86M | $581.48M | $587.77M | $562.47M | $572.92M |
| Net Debt | $-2.82B | $-3.54B | $-3.65B | $-8.44B | $-9.56B | $-10.37B | $-9.38B | $-8.50B | $-9.60B | $-8.69B | $-8.17B | $-7.06B | $-6.24B | $-5.72B | $-5.49B | $-5.73B | $-5.41B | $-4.77B | $-4.27B | $-3.02B |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-535.60M | $3.62B | $3.32B | $2.34B | $2.71B |
| Depreciation and Amortization | $207.20M | $181.30M | $148.30M | $125.60M | $109.52M |
| Deferred Income Tax | $-348.80M | $-536.50M | $-275.90M | $-154.60M | $277.34M |
| Stock Based Compensation | $698.50M | $581.20M | $491.30M | $441.40M | $429.50M |
| Change in Working Capital | $-514.80M | $-265.70M | $340.80M | $-105.20M | $-54.45M |
| Accounts Receivables | $-99.30M | $-84.10M | $-358.60M | $-274.70M | $-223.44M |
| Inventory | $-517.30M | $-322.90M | $-136.40M | $-92.80M | $-132.01M |
| Accounts Payables | $49.50M | $48.70M | $120.80M | $31.90M | $51.28M |
| Other Working Capital | $52.30M | $92.60M | $715.00M | $230.40M | $249.73M |
| Other Non Cash Items | $900.00K | $-42.60M | $103.40M | $-5.80M | $-220.00M |
| Net Cash Provided by Operating Activities | $-492.60M | $3.54B | $4.13B | $2.64B | $3.25B |
| Investments in Property Plant and Equipment | $-297.70M | $-200.40M | $-204.70M | $-235.00M | $-259.80M |
| Acquisitions Net | $- | $- | $-295.90M | $77.00M | $-418.24M |
| Purchases of Investments | $-7.44B | $-3.82B | $-740.50M | $-605.20M | $-450.72M |
| Sales Maturities of Investments | $4.47B | $934.20M | $920.00M | $499.30M | $809.91M |
| Other Investing Activities | $-499.70M | $-58.00M | $179.50M | $-77.00M | $418.24M |
| Net Cash Used for Investing Activities | $-3.77B | $-3.14B | $-321.10M | $-340.90M | $99.39M |
| Debt Repayment | $-33.60M | $-43.10M | $-82.00M | $-18.70M | $-29.00M |
| Common Stock Issued | $- | $- | $186.30M | $102.00M | $264.95M |
| Common Stock Repurchased | $-1.58B | $-653.70M | $-172.00M | $-1.56B | $-739.41M |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $120.80M | $134.60M | $186.30M | $102.00M | $263.12M |
| Net Cash Used Provided by Financing Activities | $-1.49B | $-562.20M | $-67.70M | $-1.48B | $-505.28M |
| Effect of Forex Changes on Cash | $-42.60M | $26.90M | $-29.20M | $-13.40M | $20.55M |
| Net Change in Cash | $-5.80B | $-139.70M | $3.71B | $811.20M | $2.87B |
| Cash at End of Period | $4.57B | $10.37B | $10.51B | $6.80B | $5.99B |
| Cash at Beginning of Period | $10.37B | $10.51B | $6.80B | $5.99B | $3.12B |
| Operating Cash Flow | $-492.60M | $3.54B | $4.13B | $2.64B | $3.25B |
| Capital Expenditure | $-297.70M | $-258.40M | $-204.70M | $-235.00M | $-259.80M |
| Free Cash Flow | $-790.30M | $3.28B | $3.93B | $2.41B | $2.99B |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $913.00M | $1.05B | $-3.59B | $1.10B | $968.80M | $1.04B | $915.70M | $699.80M | $818.90M | $930.50M | $810.50M | $762.10M | $770.11M | $851.93M | $66.92M | $653.14M | $604.19M | $667.43M | $837.27M | $602.75M |
| Depreciation and Amortization | $46.50M | $53.20M | $54.00M | $53.50M | $59.00M | $42.10M | $41.40M | $38.80M | $38.40M | $36.70M | $37.30M | $35.90M | $33.83M | $31.70M | $31.24M | $28.83M | $29.36M | $26.64M | $26.70M | $26.82M |
| Deferred Income Tax | $51.60M | $-123.30M | $-118.80M | $-158.30M | $-131.00M | $-115.50M | $-176.60M | $-113.40M | $148.10M | $-182.30M | $-229.40M | $-12.30M | $-41.95M | $68.24M | $-237.94M | $57.04M | $212.23M | $56.15M | $-27.74M | $36.70M |
| Stock Based Compensation | $167.80M | $184.60M | $154.20M | $191.90M | $208.60M | $130.90M | $119.30M | $122.40M | $111.50M | $135.60M | $113.90M | $130.30M | $118.61M | $103.00M | $104.62M | $115.17M | $97.03M | $99.54M | $117.19M | $115.71M |
| Change in Working Capital | $-560.20M | $112.10M | $-241.40M | $129.30M | $-838.90M | $188.90M | $245.40M | $138.90M | $-90.90M | $80.80M | $383.70M | $-32.80M | $134.68M | $-91.56M | $-164.46M | $16.14M | $-307.16M | $95.87M | $179.26M | $-22.43M |
| Accounts Receivables | $69.00M | $-51.80M | $135.10M | $-251.60M | $15.40M | $-6.10M | $-2.90M | $-90.50M | $10.20M | $-119.50M | $-84.10M | $-165.20M | $-43.53M | $-185.32M | $52.52M | $-98.37M | $-72.25M | $12.95M | $59.53M | $-223.67M |
| Inventory | $-147.50M | $-182.50M | $-107.20M | $-80.10M | $-70.00M | $-97.50M | $-72.80M | $-82.60M | $-78.30M | $-26.80M | $-33.30M | $2.00M | $-26.97M | $-18.34M | $-24.71M | $-22.79M | $-37.11M | $-30.52M | $-36.94M | $-27.45M |
| Accounts Payables | $8.40M | $66.10M | $-25.10M | $100.00K | $-31.80M | $9.20M | $35.60M | $35.70M | $159.90M | $-69.90M | $45.30M | $-14.50M | $53.94M | $2.30M | $-13.70M | $-10.64M | $35.12M | $1.46M | $412.00K | $14.29M |
| Other Working Capital | $-490.10M | $280.30M | $-244.20M | $460.90M | $-752.50M | $283.30M | $285.50M | $137.40M | $-182.70M | $297.00M | $455.80M | $144.90M | $151.25M | $109.79M | $-178.57M | $147.94M | $-232.92M | $111.99M | $156.25M | $214.41M |
| Other Non Cash Items | $-34.10M | $97.80M | $251.40M | $621.10M | $-31.90M | $-13.30M | $-10.80M | $13.40M | $52.40M | $-45.80M | $23.80M | $73.00M | $-20.30M | $-36.08M | $-155.00K | $50.73M | $-144.11M | $-37.89M | $-94.15M | $56.14M |
| Net Cash Provided by Operating Activities | $584.60M | $1.37B | $-3.75B | $1.31B | $234.60M | $1.27B | $1.13B | $899.90M | $1.08B | $955.50M | $1.14B | $956.20M | $994.99M | $927.22M | $-199.77M | $921.05M | $491.53M | $907.75M | $1.04B | $815.70M |
| Investments in Property Plant and Equipment | $-92.60M | $-67.70M | $-76.70M | $-248.40M | $-116.10M | $-40.60M | $-59.60M | $-42.10M | $-33.60M | $-54.20M | $-53.30M | $-63.60M | $-61.72M | $-52.52M | $-49.84M | $-70.93M | $-47.69M | $-174.79M | $-17.86M | $-19.45M |
| Acquisitions Net | $258.00M | $- | $- | $- | $-55.90M | $1.10M | $29.90M | $24.90M | $- | $-295.90M | $10.00M | $-0 | $77.00M | $- | $- | $- | $-418.24M | $- | $- | $-46.79M |
| Purchases of Investments | $-2.42B | $-1.13B | $-1.55B | $-2.60B | $-1.02B | $-408.30M | $-579.20M | $-1.84B | $-274.90M | $-227.70M | $-120.80M | $-117.10M | $-119.45M | $-246.29M | $-118.00M | $-121.45M | $-184.46M | $-133.89M | $-51.31M | $-81.06M |
| Sales Maturities of Investments | $1.46B | $1.11B | $1.18B | $710.50M | $218.10M | $331.20M | $334.90M | $50.00M | $484.10M | $193.60M | $112.60M | $129.70M | $47.17M | $230.86M | $103.20M | $118.07M | $475.89M | $60.74M | $141.09M | $132.18M |
| Other Investing Activities | $-30.90M | $-266.10M | $-15.00M | $-180.00M | $31.00M | $-1.10M | $-29.90M | $-24.90M | $- | $-37.80M | $-10.00M | $- | $-77.00M | $15.00M | $-15.00M | $- | $418.24M | $- | $- | $46.79M |
| Net Cash Used for Investing Activities | $-821.90M | $-348.00M | $-463.70M | $-2.14B | $-886.50M | $-117.70M | $-303.90M | $-1.83B | $175.60M | $-384.20M | $-61.50M | $-51.00M | $-134.00M | $-52.95M | $-79.64M | $-74.31M | $243.75M | $-247.94M | $71.91M | $31.67M |
| Debt Repayment | $-1.30M | $-5.40M | $-13.70M | $-13.20M | $-12.00M | $-11.30M | $-11.00M | $-10.60M | $-10.40M | $-49.50M | $-12.70M | $-12.90M | $-2.46M | $-11.10M | $-2.31M | $-8.60M | $-6.29M | $-7.84M | $-10.44M | $-4.45M |
| Common Stock Issued | $- | $8.40M | $- | $16.90M | $46.40M | $- | $- | $14.20M | $- | $- | $- | $33.70M | $- | $- | $- | $15.56M | $- | $- | $- | $79.60M |
| Common Stock Repurchased | $-425.20M | $-391.40M | $-400.80M | $-364.70M | $-152.70M | $-170.20M | $-31.40M | $-299.40M | $-2.10M | $-48.00M | $-4.40M | $-117.50M | $-369.85M | $-660.80M | $-3.60M | $-527.09M | $-151.60M | $-148.53M | $-3.08M | $-436.19M |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-33.70M | $-57.34M | $- | $- | $-3.63M | $-150.65M | $- | $- | $-5.83M |
| Other Financing Activities | $35.20M | $-82.80M | $55.90M | $20.40M | $44.90M | $16.50M | $59.70M | $15.30M | $52.70M | $37.30M | $64.80M | $35.00M | $36.07M | $15.24M | $81.04M | $16.95M | $32.70M | $15.69M | $133.55M | $81.22M |
| Net Cash Used Provided by Financing Activities | $-391.30M | $-387.50M | $-358.60M | $-357.50M | $-119.80M | $-165.00M | $17.30M | $-294.70M | $40.20M | $-60.20M | $47.70M | $-95.40M | $-336.24M | $-656.66M | $33.55M | $-518.65M | $-125.19M | $-140.68M | $120.03M | $-359.43M |
| Effect of Forex Changes on Cash | $-47.30M | $22.80M | $-2.50M | $-15.60M | $27.40M | $-22.50M | $10.00M | $12.00M | $40.80M | $-38.20M | $-25.90M | $-5.90M | $-4.93M | $-8.46M | $4.02M | $-4.03M | $17.77M | $6.16M | $3.27M | $-6.65M |
| Net Change in Cash | $-675.90M | $668.00M | $-4.58B | $-1.21B | $-744.30M | $963.20M | $857.80M | $-1.22B | $1.33B | $472.90M | $1.10B | $803.90M | $519.89M | $209.15M | $-241.84M | $324.06M | $627.86M | $525.28M | $1.23B | $481.28M |
| Cash at End of Period | $4.57B | $5.25B | $4.58B | $9.16B | $10.37B | $11.12B | $10.15B | $9.30B | $10.51B | $9.18B | $8.70B | $7.60B | $6.80B | $6.28B | $6.07B | $6.31B | $5.99B | $5.36B | $4.84B | $3.60B |
| Cash at Beginning of Period | $5.25B | $4.58B | $9.16B | $10.37B | $11.12B | $10.15B | $9.30B | $10.51B | $9.18B | $8.70B | $7.60B | $6.80B | $6.28B | $6.07B | $6.31B | $5.99B | $5.36B | $4.84B | $3.60B | $3.12B |
| Operating Cash Flow | $584.60M | $1.37B | $-3.75B | $1.31B | $234.60M | $1.27B | $1.13B | $899.90M | $1.08B | $955.50M | $1.14B | $956.20M | $995.00M | $927.20M | $-199.70M | $921.00M | $491.53M | $907.75M | $1.04B | $815.70M |
| Capital Expenditure | $-92.60M | $120.00M | $-76.70M | $-248.40M | $-116.10M | $-40.60M | $-59.60M | $-42.10M | $-33.60M | $-54.20M | $-53.30M | $-63.60M | $-61.80M | $-52.40M | $-49.90M | $-70.90M | $-47.69M | $-174.79M | $-17.86M | $-19.45M |
| Free Cash Flow | $492.00M | $1.49B | $-3.83B | $1.06B | $118.50M | $1.23B | $1.07B | $857.80M | $1.04B | $901.30M | $1.09B | $892.60M | $933.20M | $874.80M | $-249.60M | $850.10M | $443.84M | $732.95M | $1.02B | $796.25M |
Vertex Pharmaceuticals Dividends
Explore Vertex Pharmaceuticals's dividend history, including dividend yield, payout ratio, and historical payments.
Vertex Pharmaceuticals News
Read the latest news about Vertex Pharmaceuticals, including recent articles, headlines, and updates.
GILD vs. VRTX: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Gilead Sciences (GILD) or Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the better value opportunity right now?
Where Will Vertex Pharmaceuticals Be in 10 Years?
The past decade has been a game-changing one for Vertex Pharmaceuticals (VRTX 2.40%). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since gained the regulatory nod for four more and become the global leader in the CF market.
Vertex Pharmaceuticals Incorporated (VRTX) Leerink's Global Healthcare Conference 2025 (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Leerink's Global Healthcare Conference 2025 March 10, 2025 10:00 AM ET Company Participants Charlie Wagner - CFO and COO David Altshuler - Chief Scientific Officer Conference Call Participants Dave Risinger - Leerink Partners Dave Risinger Great. Well thanks very much, everyone, for joining us for our next session with Vertex.
If I Could Buy Only 1 Growth Stock, This Would Be It
There are hundreds of publicly traded companies on various equity markets worldwide. Investors choose to put their hard-earned money into specific companies based on their preferences, risk tolerance, goals, investment horizons, available capital, etc.
Vertex Announces UK MHRA Approval of ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator treatment for people living with cystic fibrosis (CF) ages 6 years and older who have at least one F508del mutation or another responsive muta.
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Vertex Pharmaceuticals Incorporated's stock has shown resilience, recovering from dips and maintaining a strong long-term growth trajectory, driven by its robust CF franchise and new product approvals. The company's 2024 performance was solid, with TRIKAFTA/KAFTRIO generating >$10bn revenues, and 2025 guidance suggesting continued growth despite some challenges. Vertex's diversification efforts include the approval of pain therapy JOURNAVX and gene therapy Casgevy, with potential multi-billion-dollar revenue contributions from these and other pipeline drugs.
Vertex Pharmaceuticals Incorporated (VRTX) TD Cowen 45th Annual Health Care Conference (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ET Company Participants David Altshuler - Executive Vice President, Global Research and CSO Stuart Arbuckle - Executive Vice President and COO Conference Call Participants Phil Nadeau - TD Cowen Phil Nadeau Good afternoon. And welcome once again to TD Cowen's 45th Annual Healthcare Conference.
Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label expansion of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor for the treatment of people with cystic fibrosis (CF) aged 2 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “We.
GILD or VRTX: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). But which of these two companies is the best option for those looking for undervalued stocks?
Vertex to Participate in Upcoming March Investor Conferences
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Stuart Arbuckle, Executive Vice President and Chief Operating Officer, and David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific Officer will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET. Charles Wagner, Executive Vice Pres.
High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models
Deshawn "DJ" Chow is one of just over 100 sickle cell patients who have undergone treatment with new gene therapies. CVS Health CEO David Joyner said private insurers and employer-sponsored health plans are looking at how to create a new risk pool arrangement to help manage the costs of the therapies.
Levi & Korsinsky Announces an Investigation on Behalf of Vertex Pharmaceuticals Incorporated (VRTX) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for VRTX.